熱門資訊> 正文

CorMetrics在公布第三季度业绩后上涨

2026-08-13 19:34

CorMedix press release (CRMD): Q2 GAAP EPS of $0.29 beats by $0.05.
Revenue of $101.93M (+156.5% Y/Y) beats by $5.88M.
The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million vs $334.57M consensus, and raises full-year adjusted EBITDA guidance to a range of $125 to $140 million. Cash OpEx guidance is narrowed to a range of $145 to $155 million.
Shares +5% PM.

More on CorMedix

CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat
CorMedix Q2 Earnings Preview
These 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocks
Seeking Alpha’s Quant Rating on CorMedix

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。